메뉴 건너뛰기




Volumn 17, Issue 4, 2012, Pages 191-196

The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients

Author keywords

Adipokines; Antihyperglycemic agents; Diabetes; Hypertension; Inflammatory biomarkers

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ROSIGLITAZONE;

EID: 84872793659     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (3)

References (51)
  • 1
    • 77951089891 scopus 로고    scopus 로고
    • International Diabetes Federation 4th edn
    • International Diabetes Federation. IDF Diabetes Atlas, 4th edn, 2009.
    • (2009) IDF Diabetes Atlas
  • 2
    • 2342466734 scopus 로고    scopus 로고
    • Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030
    • Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
    • (2004) Diabetes Care , vol.27 , pp. 1047-1053
    • Wild, S.1    Roglic, G.2    Green, A.3    Sicree, R.4    King, H.5
  • 3
    • 65949083108 scopus 로고    scopus 로고
    • Hypertension in diabetes: A call to action
    • Campbell NR, Leiter LA, Larochelle, et al. Hypertension in diabetes: A call to action. Can J Cardiol 2009;25:299-302.
    • (2009) Can J Cardiol , vol.25 , pp. 299-302
    • Campbell, N.R.1    Leiter, L.A.2    Larochelle3
  • 4
    • 0036139487 scopus 로고    scopus 로고
    • Elevated blood pressure among U.S. Adults with diabetes, 1988-1994
    • Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S. adults with diabetes, 1988-1994. Am J Prev Med 2002;22:42-8.
    • (2002) Am J Prev Med , vol.22 , pp. 42-48
    • Geiss, L.S.1    Rolka, D.B.2    Engelgau, M.M.3
  • 5
    • 0035050460 scopus 로고    scopus 로고
    • Diabetes, hypertension, and cardiovascular disease: An update
    • Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension 2001;37:1053-9.
    • (2001) Hypertension , vol.37 , pp. 1053-1059
    • Sowers, J.R.1    Epstein, M.2    Frohlich, E.D.3
  • 7
    • 77950511412 scopus 로고    scopus 로고
    • Executive summary: Standards of medical care in diabetes - 2010
    • American Diabetes Association
    • American Diabetes Association. Executive summary: Standards of medical care in diabetes - 2010. Diabetes Care 2010;33(Suppl 1):S4-10.
    • (2010) Diabetes Care , vol.33 , Issue.SUPPL. 1
  • 8
    • 54349117353 scopus 로고    scopus 로고
    • Canadian Diabetes Association clinical practice guidelines for the prevention and management of diabetes in Canada
    • Canadian Diabetes Association Clinical Practice Guidelines Expert Committee
    • Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32:51-201.
    • (2008) Can J Diabetes , vol.32 , pp. 51-201
  • 9
    • 57349160286 scopus 로고    scopus 로고
    • Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30.
    • (2009) Diabetologia , vol.52 , pp. 17-30
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 11
    • 0024511329 scopus 로고
    • Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM
    • Consoli A, Nurjhan, N, Capani, F, Gerich, J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 1989;38:550-7.
    • (1989) Diabetes , vol.38 , pp. 550-557
    • Consoli, A.1    Nurjhan, N.2    Capani, F.3    Gerich, J.4
  • 12
  • 13
    • 77649256227 scopus 로고    scopus 로고
    • Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: The DREAM trial
    • Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC. Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: The DREAM trial. Diabetes Care 2010;33:608-13.
    • (2010) Diabetes Care , vol.33 , pp. 608-613
    • Hanley, A.J.1    Zinman, B.2    Sheridan, P.3    Yusuf, S.4    Gerstein, H.C.5
  • 16
    • 69949093803 scopus 로고    scopus 로고
    • Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications
    • Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009;94:3171-82.
    • (2009) J Clin Endocrinol Metab , vol.94 , pp. 3171-3182
    • Goldberg, R.B.1
  • 17
    • 0037324289 scopus 로고    scopus 로고
    • Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease
    • Marx N, Froehlich, J, Siam L, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003;23:283-8.
    • (2003) Arterioscler Thromb Vasc Biol , vol.23 , pp. 283-288
    • Marx, N.1    Froehlich, J.2    Siam, L.3
  • 18
    • 0242543997 scopus 로고    scopus 로고
    • The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients
    • Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003;42:1757-63.
    • (2003) J Am Coll Cardiol , vol.42 , pp. 1757-1763
    • Sidhu, J.S.1    Cowan, D.2    Kaski, J.C.3
  • 19
    • 57149127132 scopus 로고    scopus 로고
    • A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: Study design and protocol
    • Gupta M, Braga MB, Verma S. A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: Study design and protocol. Can J Cardiol 2008;24:e65-9.
    • (2008) Can J Cardiol , vol.24
    • Gupta, M.1    Braga, M.B.2    Verma, S.3
  • 20
    • 1642467862 scopus 로고    scopus 로고
    • Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: The Funagata study
    • Daimon M, Oizumi T, Saitoh T, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: The Funagata study. Diabetes Care 2003;26:2015-20.
    • (2003) Diabetes Care , vol.26 , pp. 2015-2020
    • Daimon, M.1    Oizumi, T.2    Saitoh, T.3
  • 21
    • 0037031088 scopus 로고    scopus 로고
    • Adiponectin and development of type 2 diabetes in the Pima Indian population
    • Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57-8.
    • (2002) Lancet , vol.360 , pp. 57-58
    • Lindsay, R.S.1    Funahashi, T.2    Hanson, R.L.3
  • 22
    • 23844549872 scopus 로고    scopus 로고
    • Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes
    • Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4542-8.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 4542-4548
    • Mantzoros, C.S.1    Li, T.2    Manson, J.E.3    Meigs, J.B.4    Hu, F.B.5
  • 23
    • 33644698960 scopus 로고    scopus 로고
    • Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: Data from the SAPHIR Study
    • Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: Data from the SAPHIR Study. Stroke 2005;36:2577-82.
    • (2005) Stroke , vol.36 , pp. 2577-2582
    • Iglseder, B.1    Mackevics, V.2    Stadlmayer, A.3    Tasch, G.4    Ladurner, G.5    Paulweber, B.6
  • 24
    • 0034096988 scopus 로고    scopus 로고
    • Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients
    • Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
    • (2000) Arterioscler Thromb Vasc Biol , vol.20 , pp. 1595-1599
    • Hotta, K.1    Funahashi, T.2    Arita, Y.3
  • 25
    • 12744269196 scopus 로고    scopus 로고
    • Adiponectin and future coronary heart disease events among men with type 2 diabetes
    • Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005;54:534-9.
    • (2005) Diabetes , vol.54 , pp. 534-539
    • Schulze, M.B.1    Shai, I.2    Rimm, E.B.3    Li, T.4    Rifai, N.5    Hu, F.B.6
  • 26
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
    • (2008) N Engl J Med , vol.359 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.3
  • 27
    • 0035908632 scopus 로고    scopus 로고
    • C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
    • Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
    • (2001) JAMA , vol.286 , pp. 327-334
    • Pradhan, A.D.1    Manson, J.E.2    Rifai, N.3    Buring, J.E.4    Ridker, P.M.5
  • 28
    • 2942670689 scopus 로고    scopus 로고
    • Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
    • Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25.
    • (2004) Circulation , vol.109 , pp. 2818-2825
    • Ridker, P.M.1    Wilson, P.W.2    Grundy, S.M.3
  • 29
    • 28444484666 scopus 로고    scopus 로고
    • Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM
    • Coppola G, Corrado E, Muratori I, et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol 2006;106:16-20.
    • (2006) Int J Cardiol , vol.106 , pp. 16-20
    • Coppola, G.1    Corrado, E.2    Muratori, I.3
  • 30
    • 33646439400 scopus 로고    scopus 로고
    • C-reactive protein is a strong independent predictor of death in type 2 diabetes: Association with multiple facets of the metabolic syndrome
    • Linnemann B, Voigt W, Nobel W, Janka HU. C-reactive protein is a strong independent predictor of death in type 2 diabetes: Association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabetes 2006;114:127-34.
    • (2006) Exp Clin Endocrinol Diabetes , vol.114 , pp. 127-134
    • Linnemann, B.1    Voigt, W.2    Nobel, W.3    Janka, H.U.4
  • 31
  • 32
    • 33646381127 scopus 로고    scopus 로고
    • High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: A 7-year follow-up study
    • Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: A 7-year follow-up study. Diabetes Care 2006;29:329-33.
    • (2006) Diabetes Care , vol.29 , pp. 329-333
    • Soinio, M.1    Marniemi, J.2    Laakso, M.3    Lehto, S.4    Ronnemaa, T.5
  • 33
    • 0035856980 scopus 로고    scopus 로고
    • Biochemistry and molecular cell biology of diabetic complications
    • Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
    • (2001) Nature , vol.414 , pp. 813-820
    • Brownlee, M.1
  • 34
    • 20844448886 scopus 로고    scopus 로고
    • Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease
    • Signorelli SS, Malaponte G, Libra, M, et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med 2005;10:1-6.
    • (2005) Vasc Med , vol.10 , pp. 1-6
    • Signorelli, S.S.1    Malaponte, G.2    Libra, M.3
  • 35
    • 0028906790 scopus 로고
    • Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina
    • Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995;91:2125-31.
    • (1995) Circulation , vol.91 , pp. 2125-2131
    • Brown, D.L.1    Hibbs, M.S.2    Kearney, M.3    Loushin, C.4    Isner, J.M.5
  • 36
    • 0041315638 scopus 로고    scopus 로고
    • The receptor RAGE as a progression factor amplifying arachidonate- dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control
    • Cipollone, F, Iezzi, A, Fazia, M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation 2003;108:1070-7.
    • (2003) Circulation , vol.108 , pp. 1070-1077
    • Cipollone, F.1    Iezzi, A.2    Fazia, M.3
  • 37
    • 0038173265 scopus 로고    scopus 로고
    • High glucose alters matrix metalloproteinase expression in two key vascular cells: Potential impact on atherosclerosis in diabetes
    • Death AK, Fisher EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: Potential impact on atherosclerosis in diabetes. Atherosclerosis 2003;168:263-9.
    • (2003) Atherosclerosis , vol.168 , pp. 263-269
    • Death, A.K.1    Fisher, E.J.2    McGrath, K.C.3    Yue, D.K.4
  • 38
    • 77955272826 scopus 로고    scopus 로고
    • Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial
    • Bertrand, OF, Poirier, P, Rodes-Cabau, J, et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial. Atherosclerosis 2010;211:565-73.
    • (2010) Atherosclerosis , vol.211 , pp. 565-573
    • Bertrand, O.F.1    Poirier, P.2    Rodes-Cabau, J.3
  • 39
    • 40049089939 scopus 로고    scopus 로고
    • Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with type 2 diabetes mellitus
    • Kadoglou N P, Iliadis F, Angelopoulou N, Perrea D, Liapis CD, Alevizos M. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with type 2 diabetes mellitus. Diabet Med 2008;25:333-40.
    • (2008) Diabet Med , vol.25 , pp. 333-340
    • Kadoglou, N.P.1    Iliadis, F.2    Angelopoulou, N.3    Perrea, D.4    Liapis, C.D.5    Alevizos, M.6
  • 40
    • 0036481709 scopus 로고    scopus 로고
    • Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients
    • Yang, WS, Jeng, CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-80.
    • (2002) Diabetes Care , vol.25 , pp. 376-380
    • Yang, W.S.1    Jeng, C.Y.2    Wu, T.J.3
  • 41
    • 0037031267 scopus 로고    scopus 로고
    • Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
    • Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.
    • (2002) Circulation , vol.106 , pp. 679-684
    • Haffner, S.M.1    Greenberg, A.S.2    Weston, W.M.3    Chen, H.4    Williams, K.5    Freed, M.I.6
  • 42
    • 34247574161 scopus 로고    scopus 로고
    • Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes
    • Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR. Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. Diabetes Res Clin Pract 2007;77:180-7.
    • (2007) Diabetes Res Clin Pract , vol.77 , pp. 180-187
    • Reynolds, L.R.1    Kingsley, F.J.2    Karounos, D.G.3    Tannock, L.R.4
  • 43
    • 33847403059 scopus 로고    scopus 로고
    • A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes
    • e1-6
    • Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007;153:445 e1-6.
    • (2007) Am Heart J , vol.153 , pp. 445
    • Stocker, D.J.1    Taylor, A.J.2    Langley, R.W.3    Jezior, M.R.4    Vigersky, R.A.5
  • 44
    • 41749093666 scopus 로고    scopus 로고
    • Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus
    • Dolezalova R, Haluzik MM, Bosanska L, et al. Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus. Physiol Res 2007;56:741-8.
    • (2007) Physiol Res , vol.56 , pp. 741-748
    • Dolezalova, R.1    Haluzik, M.M.2    Bosanska, L.3
  • 45
    • 33749498694 scopus 로고    scopus 로고
    • Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes
    • Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006;8:650-60.
    • (2006) Diabetes Obes Metab , vol.8 , pp. 650-660
    • Rosenstock, J.1    Rood, J.2    Cobitz, A.3    Biswas, N.4    Chou, H.5    Garber, A.6
  • 46
    • 79951672869 scopus 로고    scopus 로고
    • Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naive patients with type 2 diabetes
    • Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naive patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2011;119:63-8.
    • (2011) Exp Clin Endocrinol Diabetes , vol.119 , pp. 63-68
    • Kadoglou, N.P.1    Kapelouzou, A.2    Tsanikidis, H.3    Vitta, I.4    Liapis, C.D.5    Sailer, N.6
  • 47
    • 0027406191 scopus 로고
    • Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
    • Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
    • (1993) Diabetes Care , vol.16 , pp. 434-444
    • Stamler, J.1    Vaccaro, O.2    Neaton, J.D.3    Wentworth, D.4
  • 48
    • 22144477948 scopus 로고    scopus 로고
    • Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials
    • Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-9.
    • (2005) Arch Intern Med , vol.165 , pp. 1410-1419
    • Turnbull, F.1    Neal, B.2    Algert, C.3
  • 49
    • 77950507168 scopus 로고    scopus 로고
    • Heart failure events with rosiglitazone in type 2 diabetes: Data from the RECORD clinical trial
    • Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010;31:824-31.
    • (2010) Eur Heart J , vol.31 , pp. 824-831
    • Komajda, M.1    McMurray, J.J.2    Beck-Nielsen, H.3
  • 50
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
    • (2007) N Engl J Med , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 51
    • 77955013179 scopus 로고    scopus 로고
    • Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study
    • Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A double-blind randomised controlled study. Lancet 2010;376:103-11.
    • (2010) Lancet , vol.376 , pp. 103-111
    • Zinman, B.1    Harris, S.B.2    Neuman, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.